EUVIMEDEUVIMED entdecken
Open Access

Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

Kazumasa Jojima, Akinori Minato, Hirotsugu Noguchi, Yojiro Tsuda, Naohiro Fujimoto

Cancer Diagnosis & Prognosis · 03.01.2025 · 5 (1) · 122-126

DOI: 10.21873/cdp.10420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 03.01.2025. Verfasst von Kazumasa Jojima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: This study examined the treatment outcomes of radical cystectomy (RC) for micropapillary subtype (MPS) bladder cancer treated at our hospital. Patients and Methods: Histopathological findings of RC specimens collected from 2003 to 2020 were evaluated. Recurrence-free survival (RFS) and overall survival (OS) after RC, as well as the efficacy of chemotherapy in cases of recurrence, were retrospectively assessed.

Results

Of 202 patients who underwent RC, seven (3.4%) had MPS bladder cancer. All seven patients underwent immediate RC without neoadjuvant chemotherapy. The median patient age was 58 years (range=52-71 years), and all patients were male. After RC, median RFS was 14 months (range=6-115 months), and median OS was 31 months (range=18-115 months). The clinical tumor stage was cT1 or lower in two patients (28.5%), cT2 in two patients (28.5%), and cT3 or higher in three patients (42.8%). No preoperative lymph node metastasis was observed. The pathological tumor stage was pT1 or lower in one patient (14.2%), pT2 in one patient (14.2%), and pT3 or higher in five patients (71.4%). The pathological lymph node stage was observed in five patients (71.4%). Although six of seven patients (85.7%) received adjuvant chemotherapy, all patients experienced relapse. The objective response rates of primary and secondary chemotherapy at relapse were both 33%. One patient received immune checkpoint inhibitor therapy and maintained stable disease for 12 months.

Conclusion

The recurrence rate after RC for MPS bladder cancer was high, and prognosis was poor.

Schlagwörter

Stichwörter der Autor:innen

Bladder cancerchemotherapycystectomyimmune checkpoint inhibitormicropapillaryprogrammed cell death protein 1subtypeurothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Pathology, Field of Oncology, Graduate School of Medical and Dental Science, Kagoshima University, Kagoshima, Japan.
  • Department of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Urology, Kurate Hospital, Kurate, Japan.

Zitieren

APA

Jojima, K., Minato, A., Noguchi, H., Tsuda, Y., & Fujimoto, N. (2025). Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Cancer Diagnosis & Prognosis, 5(1), 122-126. https://doi.org/10.21873/cdp.10420

Vancouver

Jojima K, Minato A, Noguchi H, Tsuda Y, Fujimoto N. Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Cancer Diagnosis & Prognosis. 2025;5(1):122-126. doi:10.21873/cdp.10420

BibTeX
@article{Jojima2025,
  author = {Jojima, Kazumasa and Minato, Akinori and Noguchi, Hirotsugu and Tsuda, Yojiro and Fujimoto, Naohiro},
  title = {Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2025},
  volume = {5},
  number = {1},
  pages = {122--126},
  doi = {10.21873/cdp.10420}
}
Kostenlos starten →